Articles tagged "Kidney transplantation"

2018 American Transplant Congress
Technical Challenges in Living Donor Kidney Transplantation – Diagnosis and Solutions
R. Öllinger,¹ K. Alqasim,¹ F. Klein,¹ N. Raschzok,¹ P. Ritschl,¹ S. Chopra,¹ N. Otto,² T. Denecke,³ U. Gerlach,¹ M. Schmelzle,¹ P. Reinke,² J. Pratschke.¹
¹Department of Surgery, Charité, Berlin, Germany; ²Department of Nephrology, Charité, Berlin, Germany; ³Department of Radiology, Charité, Berlin, Germany.
IntroductionDue to organ scarcity living donation is becoming a major source of kidneys for transplantation. Besides medical contraindications, anatomy of the kidneys may be a…
2018 American Transplant Congress
Diagnosis of Acute Renal Rejection Using Saliva Metabolome Analysis
H. Iwamoto,¹ M. Sugimoto,² O. Konnno,¹ Y. Kihara,¹ T. Yokoyama,¹ Y. Nakamura,¹ M. Sunamura,¹ T. Ueno.¹
¹Kidney Transplantation Surgery, Tokyo Medical University, Hachioji, Tokyo, Japan; ²Health Promotion and Preemptive Medicine, Research and Development Center for Minimally Invasive and Preemptive Medicine, Tokyo Medical University, Hachioji, Japan; ³Department of Digestive Surgery and Transplantation Surgery, Tokyo Medical University, Hachioji, Tokyo, Japan.
(Objective) Wide variety of biomarker discoveries have been conducted to realize low-invasive detection of rejection after renal transplantation. Metabolomics, an omics technology to enable simultaneous…
2018 American Transplant Congress
Is Kidney Transplantation Safe in Patients over 71 Years Old?
G. Andani, P. Tulissi, M. Gropuzzo, S. Crestani, C. Vallone, U. Baccarani, D. Montanaro, A. Risaliti.
Department of Kidney & Liver Transplantation, ASUIUD, Udine, Italy.
Introduction: Kidney transplantation in elderly patients is superior over dialysis as therapy for end stage renal disease (ESRD). We analyzed different parameters to evaluate patient…
2018 American Transplant Congress
Five-Year Outcomes after Randomized Treatment by Rituximab in Early Acute Antibody-Mediated Rejection in Renal Transplantation: Long Term Outcomes of the RITUX ERAH Study
E. Bailly,¹ G. Blancho,² S. Ville,² E. Morelon,³ J. Bamoulid,⁴ S. Caillard,⁵ V. Chatelet,⁶ P. Malvezzi,⁷ J. Tourret,⁸ V. Vuiblet,⁹ D. Anglicheau,¹⁰ D. Bertrand,¹¹ P. Grimbert,¹² F. Haidar,¹³ M. Hazzan,¹⁴ N. Kamar,¹⁵ P. Merville,¹⁶ C. Mousson,¹⁷ V. Pernin,¹⁸ C. Pouteil-Noble,¹⁹ R. Purgus,²⁰ J. Sayegh,²¹ P. Westeel,²² M. Büchler.¹
¹University Hospital, Tours, France; ²Institut de Transplantation-Urologie-Néphrologie, Nantes, France; ³University Hospital, Lyon Edouard Herriot, France; ⁴University Hospital, Besançon, France; ⁵University Hospital, Strasbourg, France; ⁶University Hospital, Caen, France; ⁷University Hospital, Grenoble, France; ⁸Pitié Salpêtrière Hospital, APHP, Paris, France; ⁹University Hospital, Reims, France; ¹⁰Necker Hospital, APHP, Paris, France; ¹¹University Hospital, Rouen, France; ¹²Mondor Hospital, APHP, Paris, France; ¹³Territorial Hospital, Noumea, France; ¹⁴University Hospital, Lille, France; ¹⁵University Hospital, Toulouse, France; ¹⁶University Hospital, Bordeaux, France; ¹⁷University Hospital, Dijon, France; ¹⁸University Hospital, Montpellier, France; ¹⁹University Hospital, Lyon Sud, France; ²⁰University Hospital, Marseille, France; ²¹University Hospital, Angers, France; ²²University Hospital, Amiens, France.
Background The place of rituximab in the treatment of acute antibody-mediated rejection (ABMR) is still controversial. The French multicenter double-blind, placebo-controlled RITUX ERAH study included…
2018 American Transplant Congress
The ATHENA Study: 12 Months Safety and Efficacy Data from Everolimus Combined with Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-Mycophenolate Regimen in De Novo Kidney Transplant Patients
B. Suwelack,¹ C. Sommerer,¹ D. Dragun,¹ O. Witzke,¹ C. Hugo,¹ N. Kamar,² P. Merville,² A. Hauser,¹ P. Schenker,¹ M. Junge,³ B. Nashan,¹ F. Thaiss.¹
¹Athena Study Group, Germany; ²Athena Study Group, France; ³Novartis, Pharma, Germany.
The ATHENA study was set up to compare efficacy and safety of everolimus [EVR] combined with tacrolimus [TAC] or cyclosporine A [CyA] vs. a mycophenolic…
2018 American Transplant Congress
Th17 and NK Responses Are Differentially Induced in Renal Allografts According to Recipient Murine Cytomegalovirus Dose and Strain
M. Shimamura,¹ M. Li,² S. Boddeda,¹ B. Chen,² Q. Zeng,¹ T. Schoeb,² V. Velazquez.¹
¹Center for Vaccines and Immunity and Dept. of Pediatric Infectious Diseases, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH; ²Depts. of Pediatric Infectious Diseases, Pathology, and Genetics, University of Alabama at Birmingham, Birmingham, AL.
Purpose: To study the impact of cytomegalovirus (CMV) recipient positive (R+) serostatus upon renal allograft injury, murine CMV (MCMV) D+/R+ kidney transplants using recipients infected…
2018 American Transplant Congress
Tissue Talks: Graft´s Histological Findings 10 Years after Belatacept or CNI
G. Mondragon-Ramirez,¹ N. Uribe-Uribe,² J. Arreola-Guerra,⁵ R. Reyes-Acevedo,⁵ M. Vilatoba,³ J. Furuzawa-Carballeda,⁴ A. Lopez-Toledo,¹ G. Mondragon-Salgado,¹ J. Alberu.³
¹Inst Mex de Trasplantes, Cuernavaca, Mexico; ²Pathology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ³Transplantation, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁴Immunology, Inst Nal de C. Médicas y Nutrición SZ, Mexico City, Mexico; ⁵Transplantation, C Hospital Miguel Hidalgo, Aguascalientes, Mexico.
The BENEFIT study demonstrated that 7 yrs after kidney transplantation (KT), mean eGFR, patient and graft survival, were significantly higher in the belatacept group than…
2018 American Transplant Congress
Metformin Use after Kidney Transplantation: A Safe Option in Carefully Selected Patients
F. Koraishy,¹ L. Vest,¹ Z. Zhang,¹ M. Schnitzler,¹ V. Dharnidharka,² D. Axelrod,³ R. Ouseph,¹ A. Naik,⁴ N. Lam,⁵ H. Randall,¹ T. Alhamad,² D. Segev,³ D. Brennan,³ B. Kasiske,⁶ G. Hess,⁷ K. Lentine.
¹Saint Louis Univ, St. Louis; ²Washington Univ, St. Louis; ³Lahey Clinic, Burlington; ⁴Univ Michigan, Ann Arbor; ⁵Univ Alberta, Edmonton; ⁶Johns Hopkins, Baltimore; ⁷Hennepin County, Minneapolis; ⁸Symphony Health, Conshohocken.
Recent guidelines support metformin as a therapeutic option in diabetic patients with mild to moderate renal insufficiency. The frequency and outcomes of metformin use in…
2018 American Transplant Congress
T-Cell Depletion Does Not Increase the Risk of CMV Infection in Donor-Positive, Recipient-Negative Kidney Transplants Due to the Absence of Preformed CMV-Specific Cell-Mediated Immunity
M. Jarque,¹ H. Kaminski,² L. Couzi,² E. Crespo,¹ J. Déchanet-Merville,³ S. Luque,¹ N. Montero,⁴ M. Pascual,⁵ O. Manuel,^5,6 P. Merville,² O. Bestard.^1,4
¹Nephrology Lab, IDIBELL, Barcelona, Spain; ²Nephrology Dep, Hôpital Pellegrin, Bordeaux, France; ³National Center of Scientific Research, Bordeaux, France; ⁴Nephrology Dep, Bellvitge Hospital, Barcelona, Spain; ⁵Transplantation Center, Lausanne Hospital, Lausanne, Switzerland; ⁶Infectious Diseases Dep, Lausanne Hospital, Lausanne, Switzerland.
Kidney transplants (KT) with R-/D+ CMV serostatus receiving T-cell depletion induction are considered as the highest risk population for CMV infection and long-lasting prophylaxis therapy…
2018 American Transplant Congress
Prospective, Double Blind, Randomized Trial Comparing the Use of Ketorolac and Lyrica versus SOC+placebo during Live Donor Nephrectomy for Transplant
J. Campsen,¹ T. Call,² A. Rosales,¹ C. Allen,³ A. Presson,³ R. Kim.¹
¹Trasplantation and Advanced Hepatobiliary Surgery, University of Utah, Salt Lake City, UT; ²Anesthesiology, University of Utah, Salt Lake City, UT; ³Epidemiology, University of Utah, Salt Lake City, UT.
Opioid exposure is a concern after live donation (LD) for transplant. We theorized that a protocol using pregablin pre-operation to desensitize nerves followed by ketorolac…